Few clinical and preclinical articles reported the potential usefulness of 18F-choline PET/CT in several hematological proliferative diseases. We report and incidental finding of a superscan-like pattern in a patient affected by essential thrombocythemia (ET), performing 18F-choline PET/CT for a biochemical recurrence of prostate cancer. The mild elevation of PSA values and the negativity of subsequent 68Ga-PSMA-11 PET/CT allowed to correlate the diffuse skeletal uptake detected on 18F-choline PET/CT to the underlying hematologic disease, rather than to a prostate cancer relapse.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000004474 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[F]fluorocholine PET . [Tc]sestamibi scintigraphy for detection and localization of hyperfunctioning parathyroid glands in patients with primary hyperparathyroidism: outcomes and resource efficiency.
Radiol Oncol
December 2024
Division of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Article Synopsis
- - Minimally invasive parathyroidectomy is the preferred treatment for primary hyperparathyroidism, but it relies on effective preoperative localization methods to identify overactive parathyroid tissue.
- - A study compared two groups of patients—234 who had traditional MIBI scintigraphy and 163 who had FCh-PET/CT—focusing on the efficiency and outcomes of these imaging techniques leading up to surgery.
- - Results showed that FCh-PET/CT significantly reduced imaging time by 83% and surgery time by 41% without using intraoperative hormone monitoring, suggesting it may lead to faster procedures and fewer reoperations for patients.
Testicular Incidentaloma on F-choline PET/CT in a Patient with Prostatic Adenocarcinoma.
Mol Imaging Radionucl Ther
October 2024
Mohammed V Military Training Hospital, Clinic of Nuclear Medicine, Rabat, Morocco.
Prostatic adenocarcinoma is characterized by elevated phosphatidylcholine metabolism. F-choline positron emission tomography/computed tomography (PET/CT) is widely used for patients with biochemical recurrence and a prostate-specific antigen threshold above 2 ng/mL. We report a case of a patient with high-risk prostatic adenocarcinoma undergoing F-choline PET/CT for biochemical recurrence.
View Article and Find Full Text PDFLong-term Results of Hypofractionated Radiotherapy With Intra-prostatic Boosts in Men With Intermediate- and High-risk Prostate Cancer: A Phase II Trial.
Clin Oncol (R Coll Radiol)
December 2024
Department of Radiotherapy, Clatterbridge Cancer Centre, 65 Pembroke Place, Liverpool, UK.
Aims: In the conventionally fractionated phase III FLAME prostate trial, focal boosts improved local control and biochemical disease-free survival (bDFS). We explored the toxicity and effectiveness of a moderately hypofractionated schedule with focal boosts.
Material And Methods: BIOPROP20 is a phase II single-arm non-randomised trial for intermediate- to very high-risk localised prostate cancer patients with bulky tumour volumes.
Correlation of PSA blood levels with standard uptake value maximum (SUV max ) and total metabolic tumor volume (TMTV) in 18F-PSMA-1007 and 18F-choline PET/CT in patients with biochemically recurrent prostate cancer.
Nucl Med Commun
November 2024
Department of Nuclear Medicine, Evaggelismos General Hospital, Athens and .
Objectives: In this prospective study, we investigated the correlation between prostate-specific antigen (PSA) levels in the blood of patients with prostate cancer in biochemical recurrence after radical treatment with the semiquantitative parameters standard uptake value maximum (SUV max ) and the total metabolic tumor volume (TMTV) in the metastatic foci depicted in 18F-prostate-specific membrane antigen (PSMA)-1007 and 18F-choline PET/computed tomography (CT) imaging.
Methods: We prospectively examined 104 patients with biochemical relapse of prostate cancer after primary definitive treatment. All patients underwent one 18F-PSMA-1007 and one 18F-choline PET/CT examination in randomized order within a time frame of 10 days and were followed for at least 6 months (182 ± 10 days).
ML Models Built Using Clinical Parameters and Radiomic Features Extracted from F-Choline PET/CT for the Prediction of Biochemical Recurrence after Metastasis-Directed Therapy in Patients with Oligometastatic Prostate Cancer.
Diagnostics (Basel)
June 2024
Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, 44124 Ferrara, Italy.
Unlabelled: Oligometastatic patients at [F]F-Fluorocholine (F-choline) PET/CT may be treated with metastasis-directed therapy (MDT). The aim of this study was to combine radiomic parameters extracted from F-choline PET/CT and clinical data to build machine learning (ML) models able to predict MDT efficacy.
Methods: Oligorecurrent patients (≤5 lesions) at F-choline PET/CT and treated with MDT were collected.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!